Autoimmunity to peptidyl arginine deiminase type 4 precedes clinical onset of rheumatoid arthritis

Utility of Autoantibodies as Biomarkers for Diagnosis and Staging of Neurodegenerative Diseases

“…1) (Kinloch et al, 2005;Mathsson et al, 2008;Union et al, 2002). More recently, analysis of sera from RA patients prior to their diagnosis has revealed the presence of autoantibodies against PAD4 during preclinical phases of RA (Kolfenbach et al, 2010). Another study has also suggested that ACPAs may prove useful in diagnosing RA up to 10 years before the emergence of symptoms (Arkema et al, 2013).…”

Problems of Rheumatoid Arthritis Immunopathology: Evolution of the Disease

“…Нако-нец, в сыворотках пациентов с РА обнаруживаются ауто-антитела, распознающие ПАД-4 [95], которая, как уже от-мечалось, играет ключевую роль в цитруллинировании белков. Имеются данные об обнаружении анти-ПАД ан-тител в преклиническую фазу РА, обычно в сочетании с АЦЦП [96].…”

Preclinical Rheumatoid Arthritis (Autoantibodies): An Updated Review

“…In addition, autoantibodies to hinge regions of ACPAs have been described in samples from Dutch ‘arthralgia’ patients as well as blood donors who later developed RA [29]. Kolfenbach and colleagues have also demonstrated, using serum samples from the United States Department of Defense Serum Repository, that antibodies to the enzyme peptidyl arginine deiminase-4 (PAD4) are present prior to the onset of RA [30]. In addition, using the same DoDSR sample set, Ercan and colleagues demonstrated that the glycosylation levels of autoantibodies change prior to a diagnosis of RA to a more pathogenic, hypogalactosylated state, and similar findings have been demonstrated by in the Dutch ‘arthralgia’ cohort [31]; these autoantibody changes may have some influence on the transition from asymptomatic autoimmunity to clinically-apparent RA [32].…”